EUVIMEDEUVIMED entdecken
Crossref

Knockdown of versican 1 in lung fibroblasts aggravates Lipopolysaccharide-induced acute inflammation through up-regulation of the SP1-Toll-like Receptor 2-NF-κB Axis: a potential barrier to promising Versican-targeted therapy

Lulu Xu, Weiping Hu, Jing Zhang, Jieming Qu

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Lulu Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Chongqing General Hospital and Chongqing Clinical Research Center for Geriatric Diseases, Chongqing, China; Department of P…. Hauptthemen laut MEDLINE: NF-kappa B, Toll-Like Receptor 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Innovative Research Team of High-level Local University in Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Versican participates in various pathological processes like inflammation and fibrosis and is a potential therapeutic target for inflammatory diseases. Versican 1 (V1) has increased expression in inflammatory diseases, but its role is unclear. We explored the effects of V1 on acute lung inflammation to determine whether targeting V1 had therapeutic potential. METHODS: Human fetal lung fibroblast (HFL1) was transfected with or without V1-inhibiting lentivirus and treated with LPS. The expression levels of inflammatory cytokines, V1, cellular signaling pathway and Toll-like receptors (TLRs) were detected by qPCR, ELISA and western blot. The migration and adhesion of neutrophils and monocytes to HFL1s were performed. The activity of transcriptional factors was determined by dual-luciferase reporter assay. RESULTS: Inflammatory factors increased dramatically and continuously with V1 knockdown and LPS stimulation (P < 0.01), orchestrating migration of inflammatory cells and an enhanced inflammatory reaction. V1-knockdown increased TLR2 (P < 0.01) and activated the NF-κB pathway, which was partially reversed with a TLR2 neutralizing antibody and an NF-κB inhibitor. Explosion of LPS-induced inflammation was induced by knockdown of V1 via the SP1-TLR2-NF-κB axis. CONCLUSION: Increased expression of V1 might be protective in acute inflammation, and an infection-induced cytokine storm might be a severe complication of V1-targeted interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-kappa BToll-Like Receptor 2HumansLipopolysaccharidesVersicansUp-RegulationSignal TransductionLungInflammation

Stichwörter der Autor:innen

CytokinesFibroblastsInflammationLipopolysaccharideSp1 transcription factorVersican

Substanzen

NF-kappa BToll-Like Receptor 2LipopolysaccharidesVersicans

Autor:innen und Institutionen

  • Department of Geriatrics, Chongqing General Hospital and Chongqing Clinical Research Center for Geriatric Diseases, Chongqing, China; Department of Pulmonary and Critical Care Medicine, Huadong Hospital, Shanghai Medica…
  • Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: zhang.jing@zs-hospital.sh.cn.
  • Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: jmqu0906@163.com.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Chongqing
  • Innovative Research Team of High-level Local University in Shanghai

Zitieren

APA

Xu, L., Hu, W., Zhang, J., & Qu, J. (2023). Knockdown of versican 1 in lung fibroblasts aggravates Lipopolysaccharide-induced acute inflammation through up-regulation of the SP1-Toll-like Receptor 2-NF-κB Axis: a potential barrier to promising Versican-targeted therapy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110406

Vancouver

Xu L, Hu W, Zhang J, Qu J. Knockdown of versican 1 in lung fibroblasts aggravates Lipopolysaccharide-induced acute inflammation through up-regulation of the SP1-Toll-like Receptor 2-NF-κB Axis: a potential barrier to promising Versican-targeted therapy. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110406

BibTeX
@article{Xu2023,
  author = {Xu, Lulu and Hu, Weiping and Zhang, Jing and Qu, Jieming},
  title = {Knockdown of versican 1 in lung fibroblasts aggravates Lipopolysaccharide-induced acute inflammation through up-regulation of the SP1-Toll-like Receptor 2-NF-κB Axis: a potential barrier to promising Versican-targeted therapy},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110406}
}
Kostenlos starten →